Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 150

Similar articles for PubMed (Select 21585332)

1.

Prospective observation for seven-year's highly active antiretroviral therapy in Chinese HIV-1 infected patients.

He M, Zheng YH, Zhou HY, Mamadou D, Chen Z, Chen X, Yao YH, He Y.

Curr HIV Res. 2011 Apr;9(3):160-5.

PMID:
21585332
2.

Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.

Zhou HY, Zheng YH, He Y, Chen Z, Liu M, Yin W, Liu C.

Intervirology. 2010;53(4):240-6. doi: 10.1159/000302762. Epub 2010 Mar 30.

PMID:
20357493
3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.

[Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].

Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.

Zhonghua Yi Xue Za Zhi. 2007 Nov 13;87(42):2973-6. Chinese.

PMID:
18261327
5.

Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.

Zolfo M, Schapiro JM, Phan V, Koole O, Thai S, Vekemans M, Fransen K, Lynen L.

AIDS Res Hum Retroviruses. 2011 Jul;27(7):727-35. doi: 10.1089/AID.2010.0037. Epub 2010 Nov 23.

PMID:
20854169
6.

Effective treatment of patients in a deep salvage situation with "non-active HAART": experiences with the expert advice system RADATA.

Lorenzen T, Walther I, Stoehr A, Salzberger B, Plettenberg A; Radata Study Group.

Infection. 2009 Dec;37(6):528-33. doi: 10.1007/s15010-009-9022-6. Epub 2009 Oct 13.

PMID:
19826762
7.

Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites.

Ruan Y, Xing H, Wang X, Tang H, Wang Z, Liu H, Su B, Wu J, Li H, Liao L, Li J, Wu JW, Shao Y.

Trop Med Int Health. 2010 Nov;15(11):1357-63. doi: 10.1111/j.1365-3156.2010.02621.x. Epub 2010 Sep 25.

8.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
9.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
10.

Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.

Llibre JM, Domingo P, del Pozo MA, Miralles C, Galindo MJ, Viciana I, Moreno S, Schapiro JM, Clotet B.

J Antimicrob Chemother. 2008 Jan;61(1):206-9. Epub 2007 Nov 13.

11.

Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.

Germanaud D, Derache A, Traore M, Madec Y, Toure S, Dicko F, Coulibaly H, Traore M, Sylla M, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2010 Jan;65(1):118-24. doi: 10.1093/jac/dkp412. Epub .

12.

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.

Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA.

AIDS. 2000 May 26;14(8):959-69.

PMID:
10853977
13.

Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.

Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S.

Antivir Ther. 2008;13(7):927-36.

PMID:
19043927
14.

Prevalence of drug-resistant HIV-1 in rural areas of Hubei province in the People's Republic of China.

Luo M, Liu H, Zhuang K, Liu L, Su B, Yang R, Tien P, Zhang L, Gui X, Chen Z.

J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):1-8. doi: 10.1097/QAI.0b013e31818ffcdc.

PMID:
19295329
15.

Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.

Plana M, Martínez C, García F, Maleno MJ, Barceló JJ, García A, Lejeune M, Vidal C, Cruceta A, Miró JM, Pumarola T, Gallart T, Gatell JM.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):429-34.

PMID:
11981357
16.

Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.

Miró JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, Ribera E, Arrizabalaga J, Loncá M, Cruceta A, de Lazzari E, Fuster M, Podzamczer D, Plana M, Gatell JM; Advanz Study Group.

AIDS Res Hum Retroviruses. 2010 Jul;26(7):747-57. doi: 10.1089/aid.2009.0105.

PMID:
20624069
17.

Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts.

Calmy A, Petoumenos K, Lewden C, Law M, Bocquentin F, Hesse K, Cooper D, Carr A, Bonnet F; Aquitaine Cohort, Australian HIV Observational Database and St Vincent's Hospital Cohort study groups.

HIV Med. 2007 Apr;8(3):171-80.

PMID:
17461861
18.

HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens.

Nicastri E, Palmisano L, Sarmati L, D'Ettorre G, Parisi S, Andreotti M, Buonomini A, Pirillo FM, Narciso P, Bellagamba R, Vullo V, Montano M, Di Perri G, Andreoni M.

Curr HIV Res. 2008 May;6(3):261-6.

PMID:
18473790
19.

Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.

Bongiovanni M, Chiesa E, Di Biagio A, Meraviglia P, Capetti A, Tordato F, Cicconi P, Biasi P, Bini T, d'Arminio Monforte A.

J Antimicrob Chemother. 2005 Jun;55(6):1003-7. Epub 2005 Apr 11.

20.

Paediatric antiretroviral therapy audit in South London.

Doerholt K, Sharland M, Ball C, DuMont G.

HIV Med. 2002 Jan;3(1):44-8.

PMID:
12059950
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk